Enquirer Consulting Group

Reachable Buyer Map

Prepared for Faidra Angelikaki · FAMAR · August 2026
Your thread with our magazine side stalled, so here is the more useful way back. This is the buyer set for contract development and manufacturing in Europe: who actually signs an outsourcing decision, the groups those people sit in, and roughly how many there are. It describes the market rather than your business, and there is nothing to buy at the end of it.
European pharmaceutical companies
The core outsourcing buyer, and far smaller than the register suggests. Most registered manufacturers are tiny; the budget concentrates in the few hundred companies selling a portfolio across more than one country, where an internal capacity gap turns into an external program.
Who signs: head of external manufacturing, VP of technical operations, supply chain director, head of quality, procurement category lead.
4,000 to 5,000
registered pharmaceutical manufacturing enterprises across the EU; the buying layer inside that is a few hundred companies of real scale
Generic and branded generic companies
The most consistent outsourcers on the page, because cost and capacity are the whole argument in that model. They also move fastest, since a transfer decision does not have to survive a brand conversation.
Who signs: chief operating officer, head of supply, portfolio and lifecycle managers, procurement director.
300 to 400
European generic and biosimilar companies of scale, out of a much longer tail of national players
Consumer health and personal care brand owners
The segment lists get wrong. A company that owns the label but outsources production registers as a consumer goods business, not as a medicine maker, so it never appears in a pharmaceutical count at all. Anyone buying a list of pharmaceutical companies reaches the plants and misses the brands.
Who signs: general manager, head of supply chain, innovation lead, category director, quality manager.
Not in any pharmaceutical register
brand owners are identified brand by brand rather than counted; the layer is materially larger than the manufacturing figure above
Companies outside Europe that need a European route
Approval in one region creates a supply problem in another. A company with an approved or nearly approved product and no European footprint needs manufacturing, release and logistics inside the region, and it needs them on a launch timeline rather than a procurement one.
Who signs: chief technical officer, head of CMC, VP of supply chain, head of business development.
45 to 55 a year
novel medicines cleared by the United States regulator each year, before the far larger set already approved and looking for a European supply route
Retail and pharmacy own label
A pharmaceutical decision made inside a retail organization, which is why pharmaceutical selling rarely reaches it. The buyer thinks in categories, margin and shelf dates, and qualifies a manufacturer on reliability rather than on science.
Who signs: private label director, category buyer, supply chain manager, quality lead.
Counted in groups, not companies
European pharmacy chains, buying groups and retail health brands; the buying unit is the group, and there are far fewer of those than there are stores
Biotech and specialty companies at first launch
The highest value conversation on the page and the hardest to time. The moment that matters is the year before first approval, when manufacturing has to be locked and the company has no operations of its own. Miss it and the product is placed for its whole life.
Who signs: chief technical officer, head of manufacturing, head of CMC, and at smaller companies the chief executive.
Identified by asset, not by list
there is no register of companies approaching a first approval without a manufacturing route; they are found by tracking assets through the approval process

Where the openings are

1
The buy is triggered by an event, never by a season. A site closure, a capacity squeeze, a product divestment, a launch in a new market, a supplier that failed an inspection. Those events surface in public filings and trade reporting weeks or months before a request for proposal exists. Watching a few thousand companies for them is mechanical work, and it is the whole advantage.
2
Two buyer types, and they do not talk to each other. Technical operations buys on capability, audit history and qualification over a long cycle. Consumer care brand owners buy commercially and move quickly. Same page of a directory, different language, different door. One channel usually keeps returning to whichever of the two it was built for.
3
The decision is a committee and one channel reaches one seat. Quality, supply chain, procurement and business development each hold a veto and each hears about a supplier differently. Reaching the sponsor alone produces a warm meeting and a slow no. Reaching all four by name is a targeting job rather than a persuasion one.
4
Reputation carries inside Europe and stops at the water. Seventy five years of history is a strong opening line to a company that already knows the region. To a company outside it, choosing where to make and release a product for the first time, it is only useful if someone puts it in front of them. That set is reachable, and across the sector it is barely worked.
Built from public market data, counts banded deliberately. Enterprise counts come from published European industry statistics and describe registered companies rather than buying units. Brand owners, retail own label groups and companies approaching a first approval are not enumerated in any pharmaceutical register, so they are described rather than counted.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com